134 related articles for article (PubMed ID: 9248260)
1. [Cost effectiveness analysis of FDG-PET in the differential diagnosis and staging of lung cancer in Japan].
Kubota K; Yamada S; Fukuda H; Tanida T; Saitou Y; Takahashi J; Yamada K
Kaku Igaku; 1997 May; 34(5):329-36. PubMed ID: 9248260
[TBL] [Abstract][Full Text] [Related]
2. Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of non-small-cell lung carcinoma.
Gambhir SS; Hoh CK; Phelps ME; Madar I; Maddahi J
J Nucl Med; 1996 Sep; 37(9):1428-36. PubMed ID: 8790186
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of FDG-PET in staging non-small cell lung cancer: the PLUS study.
Verboom P; van Tinteren H; Hoekstra OS; Smit EF; van den Bergh JH; Schreurs AJ; Stallaert RA; van Velthoven PC; Comans EF; Diepenhorst FW; van Mourik JC; Postmus PE; Boers M; Grijseels EW; Teule GJ; Uyl-de Groot CA;
Eur J Nucl Med Mol Imaging; 2003 Nov; 30(11):1444-9. PubMed ID: 14579081
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of FDG-PET for staging non-small cell lung cancer: a decision analysis.
Scott WJ; Shepherd J; Gambhir SS
Ann Thorac Surg; 1998 Dec; 66(6):1876-83; discussion 1883-5. PubMed ID: 9930463
[TBL] [Abstract][Full Text] [Related]
5. Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of non-small-cell lung carcinoma.
Makler PT
J Nucl Med; 1997 Jul; 38(7):1173-4. PubMed ID: 9225819
[No Abstract] [Full Text] [Related]
6. [PET with (18)F-fluorodeoxyglucose for staging of non-small cell lung cancer].
Weber WA; Dietlein M; Hellwig D; Kirsch CM; Schicha H; Schwaiger M
Nuklearmedizin; 2003 Aug; 42(4):135-44. PubMed ID: 12937692
[TBL] [Abstract][Full Text] [Related]
7. Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphoma.
Hoh CK; Glaspy J; Rosen P; Dahlbom M; Lee SJ; Kunkel L; Hawkin RA; Maddahi J; Phelps ME
J Nucl Med; 1997 Mar; 38(3):343-8. PubMed ID: 9074514
[TBL] [Abstract][Full Text] [Related]
8. Decision-tree sensitivity analysis for cost-effectiveness of chest 2-fluoro-2-D-[(18)F]fluorodeoxyglucose positron emission tomography in patients with pulmonary nodules (non-small cell lung carcinoma) in Japan.
Kosuda S; Ichihara K; Watanabe M; Kobayashi H; Kusano S
Chest; 2000 Feb; 117(2):346-53. PubMed ID: 10669673
[TBL] [Abstract][Full Text] [Related]
9. Role of
Delgado Bolton RC; Calapaquí-Terán AK; Giammarile F; Rubello D
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2019; 38(4):229-233. PubMed ID: 31202725
[TBL] [Abstract][Full Text] [Related]
10. Differentiating benign from malignant lung lesions using "quantitative" parameters of FDG PET images.
Hübner KF; Buonocore E; Gould HR; Thie J; Smith GT; Stephens S; Dickey J
Clin Nucl Med; 1996 Dec; 21(12):941-9. PubMed ID: 8957608
[TBL] [Abstract][Full Text] [Related]
11. [Decision tree sensitivity analysis for cost-effectiveness of chest FDG-PET in patients with a pulmonary tumor (non-small cell carcinoma)].
Kosuda S; Ichihara K; Watanabe M; Kobayashi H; Kusano S
Kaku Igaku; 1998 Jul; 35(6):395-404. PubMed ID: 9753918
[TBL] [Abstract][Full Text] [Related]
12. PET in lung cancer staging.
Coleman RE
Q J Nucl Med; 2001 Sep; 45(3):231-4. PubMed ID: 11788815
[TBL] [Abstract][Full Text] [Related]
13. Consistency of FDG-PET accuracy and cost-effectiveness in initial staging of patients with Hodgkin lymphoma across jurisdictions.
Cerci JJ; Trindade E; Buccheri V; Fanti S; Coutinho AM; Zanoni L; Linardi CC; Celli M; Delbeke D; Pracchia LF; Pitela FA; Soares J; Zinzani PL; Meneghetti JC
Clin Lymphoma Myeloma Leuk; 2011 Aug; 11(4):314-20. PubMed ID: 21816369
[TBL] [Abstract][Full Text] [Related]
14. Analysis models to assess cost effectiveness of the four strategies for the work-up of solitary pulmonary nodules.
Tsushima Y; Endo K
Med Sci Monit; 2004 May; 10(5):MT65-72. PubMed ID: 15114278
[TBL] [Abstract][Full Text] [Related]
15. Primary staging of lymphomas: cost-effectiveness of FDG-PET versus computed tomography.
Klose T; Leidl R; Buchmann I; Brambs HJ; Reske SN
Eur J Nucl Med; 2000 Oct; 27(10):1457-64. PubMed ID: 11083533
[TBL] [Abstract][Full Text] [Related]
16. PET scanning said to save money and improve staging of lung cancer.
Oncology (Williston Park); 1995 Nov; 9(11):1200. PubMed ID: 8703689
[No Abstract] [Full Text] [Related]
17. Medical economics of whole-body FDG PET in patients suspected of having non-small cell lung carcinoma--reassessment based on the revised Japanese national insurance reimbursement system.
Abe K; Kosuda S; Kusano S
Ann Nucl Med; 2003 Dec; 17(8):649-55. PubMed ID: 14971606
[TBL] [Abstract][Full Text] [Related]
18. Quantitative volumetric CT-histogram analysis in N-staging of 18F-FDG-equivocal patients with lung cancer.
Flechsig P; Kratochwil C; Schwartz LH; Rath D; Moltz J; Antoch G; Heussel CP; Rieser M; Warth A; Zabeck H; Kauczor HU; Haberkorn U; Giesel FL
J Nucl Med; 2014 Apr; 55(4):559-64. PubMed ID: 24525209
[TBL] [Abstract][Full Text] [Related]
19. Decision-tree sensitivity analysis for cost-effectiveness of whole-body FDG PET in the management of patients with non-small-cell lung carcinoma in Japan.
Kosuda S; Ichihara K; Watanabe M; Kobayashi H; Kusano S
Ann Nucl Med; 2002 Jun; 16(4):263-71. PubMed ID: 12126096
[TBL] [Abstract][Full Text] [Related]
20. Fluorodeoxyglucose-positron emission tomography in the detection and staging of lung cancer.
Sazon DA; Santiago SM; Soo Hoo GW; Khonsary A; Brown C; Mandelkern M; Blahd W; Williams AJ
Am J Respir Crit Care Med; 1996 Jan; 153(1):417-21. PubMed ID: 8542152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
